Integrated system of the tailor-made cancer treatment based on the expression profiling and bioinformatic analyses

在本研究中，我们对手术切除的肺癌病例进行了高度复杂的基因组学和蛋白质组学分析，这是日本癌症死亡的头号原因，以便为定制癌症治疗的综合系统奠定基础。因此，我们能够显示存在表达谱定义的肺腺癌异质性，这似乎与遗传改变的状态和术后临床行为如预后密切相关。此外，新提出的分类可以区分一部分患者，这些患者最有可能受益于针对EGFR介导的信号传导的辅助分子靶向治疗。此外，我们能够建立一个基础，为未来的研究应用蛋白质组学的血液标本，如血清。这些发现应该有助于进一步发展基因组学和/或蛋白质组学为基础的方法，以量身定制的药物来征服这种毁灭性的疾病。

In this study, we have carried out highly sophisticated genomics and proteomics analyses of surgically resected cases of lung cancer, which has been the number one cause of cancer deaths in Japan, in order to establish the foundation for the integrated system of the tailor-made cancer treatment. As a result, we were able to show the presence of expression-profile-defined heterogeneity of pulmonary adenocarcinomas, which appeared to be correlated well with the status of genetic alterations and postoperative clinical behaviors such as prognosis. Furthermore, the newly proposed classification could distinguish a subset of patients, which most likely benefit from adjuvant molecular targeted therapy against EGFR-mediated signaling. In addition, we were able to establish the foundation for future studies on the applied proteomics of blood specimens such as serum. These findings should aid further development of genomics and/or proteomics-based approach towards the tailor-made medicine to conquer this devastating illness.